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ABSTRACT: The Diels-Alder reaction, a [4+2] 
cycloaddition of a conjugated diene to a dienophile, is 
one of the most powerful reactions in synthetic 
chemistry. Biocatalysts capable of unlocking new and 
efficient Diels-Alder reactions would have major 
impact. Here we present a molecular-level description of 
the reaction mechanism of the spirotetronate cyclase 
AbyU, an enzyme shown here to be a bona fide natural 
Diels-Alderase. Using enzyme assays, X-ray crystal 
structures and simulations of the reaction in the enzyme, 
we reveal how linear substrate chains are contorted 
within the AbyU active site to facilitate a transannular 
pericyclic reaction. This study provides compelling 
evidence for the existence of a natural enzyme evolved 
to catalyze a Diels-Alder reaction, and shows how 
catalysis is achieved.  
The Diels-Alder reaction is a [4+2] cycloaddition that 
involves the reorganization of a six-electron system to 
form a cyclohexene.1 This transformation is of major 
synthetic value for the preparation of substituted six-
membered rings with the creation of up to four new 
stereocenters.2–5 Development of protein catalysts for 
these reactions is a major goal in biocatalysis, and would 
potentially enable new, efficient and ‘green’ synthetic 
routes to a wide variety of valuable bioactive 
compounds. Whilst a small number of natural enzymes 
have been shown to be capable of catalyzing [4+2] 
cycloaddition reactions6–13 the molecular details of how 
these transformations are achieved, and whether they do 
indeed proceed via a formal Diels-Alder route, remain 
unknown.14–16 Detailed mechanistic studies of protein-
catalyzed Diels-Alder reactions have to date been 
restricted to de novo designed enzymes and catalytic 
antibodies.17,18 These valuable test subjects, however, 
exhibit poor catalytic efficiencies, limiting their value as 
biocatalysts.19,20 Establishing whether natural enzymes 
have evolved Diels-Alderase activity, and in particular, 
how such catalysis is achieved at the molecular level, is 
crucial for the development of efficient protein Diels-
Alder catalysts.15-18,21  
We focus on the putative natural Diels-Alderase AbyU, 
from the abyssomicin C biosynthetic pathway. The 
spirotetronate antibiotic abyssomicin C (1), first isolated 
from the marine actinomycete Verrucosispora maris 
AB-18-032, is a potent inhibitor of bacterial folate 
metabolism effective against Mycobacterium 
tuberculosis and multi-drug resistant clinical isolates of 
Staphylococcus aureus.22 The biosynthesis of this 
compound proceeds via the formation of a 
heterobicyclic ring system, comprising a tetronic acid 
ring (4-hydroxy-[5H]furan-2-one) spiro-linked to 
cyclohexene23 (Figure 1). Formation of this carbocycle 
is postulated to occur via an enzyme-catalyzed 
intramolecular [4+2] cycloaddition between the 
exocyclic methylene group and conjugated diene of 
4.24,25 This transformation could conceivably progress 
via a formal Diels-Alder reaction. Studies of enzymes 
from other spirotetronate biosynthetic pathways have 
demonstrated the presence of a stand-alone cyclase that 
facilitates [4+2] cycloaddition.12,13 However, the 
molecular basis of how this reaction is performed and 
whether it does indeed progress via a concerted 
mechanism are unknown. Given that spirotetronate 
cyclases share no amino acid sequence identity to other 
putative natural Diels-Alderases,4,6–13 it is likely that 
these enzymes represent a distinct protein scaffold in 
which a Diels-Alder reaction may take place.  
An N-terminally hexa-histidine tagged variant of AbyU 
was recombinantly over-expressed in E. coli B834(DE3) 
cells and purified to homogeneity. Purified recombinant 
 AbyU was found to be a homogeneous, dimeric species 
in solution, of >95% purity (Figure S1).  
 
Figure 1. Proposed abyssomicin C biosynthetic pathway, 
synthetic substrate analogues (6 and 7) and biosynthesized 
spirotetronates (8 and 9). During the biosynthesis of 
abyssomicin C the heptaketide product 2 of the AbyB1-3 
polyketide synthase is condensed with glycerate, presented 
on the free-standing acyl carrier protein AbyA3, to form a 
5-membered ring in 3. Acetylation of 3 followed by 
elimination, catalyzed by the AbyA4/AbyA5 enzyme 
couple, introduces the exocyclic methylene of 4. 
Intramolecular [4+2] cycloaddition of 4 is catalyzed by 
AbyU and yields the spirotetronate abyssomicin C 
precursor 5. Structural and functional studies of AbyU 
reported herein were conducted using substrate analogues 6 
and 7, which were enzymatically converted to 8 and 9 
respectively. 
Substrate 6, an analogue of the proposed AbyU substrate 
4 (Figure 1) was synthesized and incubated with AbyU 
for 30 mins at 25 °C. Analysis of the resulting reaction 
mixture by HPLC indicated that a single product had 
been formed with the same retention time as a standard 
of 8, prepared by heating diketone 6 for 2 days in 
chloroform (Figure 2). The mass of this product (m/z = 
367.53) and 1H-NMR of the crude material were in 
accord with the spirocyclic product 8 (Figure S2 and SI).  
There was no evidence of cyclization occurring in 
control reactions lacking enzyme, or containing heat-
denatured AbyU (Figure 2). Steady-state kinetic 
characterization of the AbyU catalyzed conversion of 6 
to 8 gave kcat = 564 ± 43 min-1, Km = 102 ± 17 μM and 
kcat/Km = 5.5 ± 0.2 min-1μM-1. This compares with a rate 
for the non-AbyU catalyzed reaction of k = 0.014 min-1, 
consistent with a > 4 x 104 fold enhancement in rate in 
the presence of enzyme (Figure S3). Whilst these data 
give compelling support for an AbyU mediated [4+2] 
cycloaddition, diketone 6 is known to slowly undergo a 
Diels-Alder reaction at room temperature (40% 
conversion after one week in chloroform26 and Figure 
S3).  To further explore the potential value of AbyU, a 
substrate less prone to undergo cyclization was 
investigated.  
Since in general, electron-deficient dienophiles are 
favored in Diels-Alder reactions, a mixture of epimeric 
alcohols 7, the synthetic precursor of diketone 6, was 
selected. Neither incubation of 7 in aqueous buffer for 
24 hrs, nor heating of 7 in chloroform for 2 days gave 
the cycloadduct 9. In contrast, incubation of 7 with 
AbyU for 30 mins at 25 °C yielded two products (Figure 
2) with the correct mass (m/z=369.63) for the epimeric 
cycloaddition products 9 (Figure S2), indicating that an 
intramolecular [4+2] cycloaddition had taken place. No 
synthetic standard of 9 was available for comparison. To 
circumvent this, the mixture of 9 from the AbyU-
catalyzed reaction was purified by preparative TLC and 
oxidized using Dess-Martin periodinane, to yield a less 
polar product (Figure 2 and SI), which exhibited a 
retention profile, mass spectrum (m/z=367.53), and 1H 
NMR data in accord with the synthetic spirotetronate 8. 
No product was detected in control reactions with heat-
denatured AbyU. Together, these data show that AbyU is 
capable of catalyzing [4+2] cycloaddition reactions, 
including one that cannot be readily achieved under 
standard conditions of prolonged heating. 
 
Figure 2. HPLC analysis demonstrating AbyU catalyzed 
[4+2] cycloaddition.  Traces are shown for assay mixes 
comprising: (a), synthetic standard of diketone 6; (b), 6 
incubated with 280 μM AbyU; (c), 6 incubated with 280 
μM heat denatured AbyU; (d), synthetic standard of Diels-
Alder product 8; (e), synthetic standard of diol 7 (as a 
mixture of epimeric alcohols); (f), 7 incubated with 280 μM 
AbyU; (g), 7 incubated with 280 μM heat denatured AbyU; 
(h), synthetic standard of Diels-Alder product 8; (i), 
product from the purification of 9 isolated from (f) 
followed by oxidation using Dess-Martin periodinane to 
Figure 2. 
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 give 8. Standard incubation conditions comprised 10 mM 
substrate with or without AbyU for 30 mins at 25 oC.  
To analyze the molecular basis of the AbyU-catalyzed 
cycloaddition, we determined the crystal structure of the 
enzyme (Figure 3).  
 
Figure 3. Crystal structure of AbyU and substrate binding 
mode. (a), Overall fold of the AbyU dimer. Individual 
monomers are colored blue and green respectively. (b), 
Cut-away view through crystal structure of AbyU, 
revealing the size and location of the enzyme active site. 
The protein is shown in space filling representation and is 
colored by electrostatic surface potential. The residues 
Glu19 and Arg122 are shown in stick format and colored 
by atom. (c), Detailed view of the AbyU active site 
highlighting key residues and bound molecule of HEPES. 
Coloring is by atom. (d), Superposition of the 
computationally predicted binding modes of 4, 5 and the 
atropisomer of 5 within the active site of AbyU.  
For the purposes of phase determination, a mutant of 
AbyU (AbyU_DM) was generated in which the residues 
Leu73 and Leu139 were replaced with 
selenomethionines, using methionine encoding codons 
(Figure S4). AbyU_DM was recombinantly over-
expressed in E. coli and purified to homogeneity. As 
with AbyU, AbyU_DM was found to be dimeric in 
solution (Figure S1). The crystal structure of AbyU_DM 
was determined to 1.7 Å resolution using the single 
wavelength anomalous dispersion (SAD) method as 
applied to selenomethionine (SeMet) labeled crystals of 
AbyU_DM. This structure was subsequently used as a 
molecular replacement search model to elucidate the 
crystal structure of AbyU. The Cα RMSD between 
AbyU_DM and AbyU is 0.4 Å (Figure S5). Both 
unlabeled and SeMet labeled AbyU_DM catalyzed the 
conversion of 6 to 8 (Figure S6), confirming their 
catalytic competency.  
AbyU is a homodimer comprised of two eight stranded 
anti-parallel β-barrels with (+1)8 topology (Figure 3). 
The central channel of each barrel is sealed at one end 
by a salt bridge formed by the side-chains of Glu19 and 
Arg122 and is capped at the other by a largely 
hydrophobic loop formed by the β1-β2 linker (residues 
Asp26-Gly36; Figure 3). Molecular dynamics 
simulations demonstrate the flexible nature of the 
capping loop and its ability to gate active site access 
(Figure S7). The central channel of the barrel forms an 
extended largely hydrophobic cavity of ~720 Å3 that 
constitutes the active site of the enzyme, formed by the 
side chains of the residues Val21, Phe41, Phe60, Tyr76, 
Phe95, Tyr106, Trp124 and Met126 (Figure 3). Electron 
density corresponding to a single bound HEPES 
molecule is observed in the active sites of each of the 8 
copies of AbyU and three of the four copies of 
AbyU_DM that comprise their respective asymmetric 
units (Figures 3 and S5).  
AbyU’s closest structural homolog is the allene oxide 
cyclase PpAOC2:27 a more elaborated eight stranded 
barrel with a significantly different active site 
architecture (Figure S8). Comparison of the sequence of 
AbyU with those of other known spirotetronate cyclases 
reveals minimal sequence conservation (Figure S9), 
raising the intriguing possibility that mutation of the 
internal cavity of barrel-like structures may offer a route 
to generating enzymes capable of performing [4+2] 
cycloaddition reactions using a range of substrates. 
To establish the catalytic mechanism of AbyU, we first 
investigated the binding mode of the substrate associated 
with the reaction. Docking of 4, 5 and the atropisomer of 
5 in the active site supports a binding mode where the 
substrate dienophile is positioned next to Phe41 and the 
diene close to Trp124 (Figures 3 and S10). In this 
binding mode, a hydrogen bond is formed between 
Tyr76 and the lactone carbonyl, which may contribute to 
substrate specificity. Binding is largely hydrophobic, 
with good steric complementarity between the enzyme 
and substrate. In the docked conformation of 4, the C13-
C14 and C10-C15 distances (bonds formed in the 
product) are 3.6 and 3.9 Å, respectively. This indicates 
that the enzyme active site accommodates the substrate 
in a potentially reactive Michaelis conformation. 
Molecular dynamics (MD) simulations of the enzyme 
with product 5 bound show that the binding mode 
obtained from docking is stable. Little structural change 
of the enzyme is required to accommodate the substrate; 
comparison of MD simulations of the apo and substrate-
bound enzymes primarily show changes in the loop 
covering the active site cavity (residues 26-36), which 
becomes more ordered on substrate binding (Figure S7).  
Quantum mechanics/molecular mechanics (QM/MM) 
molecular dynamics simulations, which incorporate the 
effects of the enzyme on the reaction28, reveal that the 
reaction in the enzyme proceeds via a concerted, 
asynchronous Diels-Alder mechanism (Figures S10 and 
 S11). They show that the substrate can react from the 
binding mode described above. The structural and 
electronic properties of the transition state (Figures S10 
and S11) indicate that AbyU is indeed a true Diels-
Alderase. Free-energy profiles of the reaction were 
calculated at the SCC-DFTB/ff14SB QM/MM level, 
with the reaction simulated in the reverse direction, 5 to 
4. The active site is well organized to catalyze the 
reaction and the interactions noted above are maintained 
throughout. In the transition state, C13-C14 bond 
formation is more advanced than C10-C15 bond 
formation, which occurs predominantly on the downhill 
path to the product (Figure S10). Higher-level density 
functional theory calculations (M06-2X/6-31G(d,p)) 
confirm the identification of the transition state structure 
and the order of bond formation (Figure S11). Both 
levels of theory thus show that the [4+2] cycloaddition 
of 4 to 5 occurs via an asynchronous concerted Diels-
Alder mechanism. The transition state structures 
calculated for the reaction of the isolated substrate are 
similar to those in the enzyme, which indicates that the 
primary catalytic function of the enzyme is to provide a 
preorganized active site that binds a reactive 
conformation of the substrate, from which the reaction 
can occur with a relatively low free energy barrier.  
In summary, we report the structural and functional 
characterization of the spirotetronate cyclase AbyU, 
establishing the molecular basis of the [4+2] 
cycloaddition reaction catalyzed by this enzyme. AbyU 
is a co-factor independent, stand-alone Diels-Alderase 
with a low-molecular weight beta-barrel scaffold. The 
simplicity of this enzyme makes it a compelling and 
practical target for engineering. It has further been 
shown capable of accepting and acting upon non-natural 
substrates, including those that do not readily cyclize 
upon heating. This study presents unequivocal evidence 
of the existence of a natural enzyme capable of 
catalyzing a formal Diels-Alder reaction and paves the 
way for the exploitation of AbyU as a biocatalyst for 
industrial applications and the designed synthesis of 
novel bioactive compounds. 
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